< Brochure Homepage | Faculty Index | Pathology Homepage



Email mgoggins@jhmi.edu
Phone (410) 955-3511

Related Websites
PC Early Detection Lab


Michael G. Goggins, M.D.

Primary Appointment in Pathology; Secondary Appointments in Medicine, Oncology
Member, Graduate Program in Pathobiology


My research is focused on pancreatic cancer. The main focus of my research is improving the early detection of pancreatic cancer. Much of the early detection research is directed towards the Cancer of the Pancreas Screening studies which are evaluating the utility of screening individuals with an increased risk of developing pancreatic cancer based on their inherited risk. The focus of the CAPS studies is evaluating diagnostic tests that could improve the development of pancreatic cancer and pancreatic cancer precursor lesions. The search for diagnostic tests involves the characterizing the molecular differences between pancreatic cancers and their precursor lesions and normal pancreas. Improving the early detection of pancreatic cancer requires a more comprehensive assessment of pancreatic cancer risk. I work with other members of the pancreatic cancer team at Hopkins to better understand the genetic and environmental risk factors and comorbidities that contribute to pancreatic cancer risk.

Publications
Yu J, Blackford A, Dal Molin M, Wolfgang C, Goggins M. Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut 2015;epub Jan31. PMC4520782

Eshleman JR, Norris AL, Sadakari Y, Debeljak M, Borges M, Harrington C, Lin E, Brant A, Barkley T, Almario JA, Topazian M, Farrell J, Syngal S, Lee JH, Yu J, Hruban RH, Kanda M, Canto MI, Goggins M. KRAS and GNAS Mutations in Pancreatic Juice Collected From the Duodenum of Patients at High Risk for Neoplasia Undergoing Endoscopic Ultrasound. Clin Gastroenterol Hepatol 2015;13:963-9. PMC4404180.

Sadakari Y, Kanda M, Maitani K, Borges M, Canto MI, Goggins M. Mutant KRAS and GNAS DNA Concentrations in Secretin-Stimulated Pancreatic Fluid Collected from the Pancreatic Duct and the Duodenal Lumen. Clin Transl Gastroenterol 2014;in press. PMCID in process

Vincent A, Hong SM, Hu C, Omura N, Young A, Kim H, Yu J, Knight S, Ayars M, Griffith M, Van Seuningen I, Maitra A, Goggins M. Epigenetic silencing of EYA2 in pancreatic adenocarcinomas promotes tumor growth. Oncotarget 2014; 5:2575-2587. PMC4058028

Kim H, Saka B, Knight S, Borges M, Childs E, Klein AP, Wolfgang CL, Herman JM, Adsay V, Hruban RH, Goggins M. Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis. Clin Cancer Res 2014;20: 1865-72 PMC3975663

Li A, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, Goggins M. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res 2013;19:3600-3610 PMC3707520

Kanda M, Sadakari Y, Borges M, Topazian M, Farrell J, Syngal S, Lee J, Kamel I, Lennon AM, Knight S, Fujiwara S, Hruban RH, Canto MI, Goggins M. Mutant TP53 in Duodenal Samples of Pancreatic Juice from Patients with Pancreatic Cancer or High-Grade Dysplasia. Clin Gastroenterol Hepatol 2012:11:719-30 PMC3600161

Yu J, Li A, Hong SM, Hruban R, Goggins, M. MicroRNA Alterations of Pancreatic Intraepithelial Neoplasms (PanINs). Clin Cancer Res 2012; 8(4):981-92 PMC3288338

Amato E, Molin MD, Mafficini A, Yu J, Malleo G, Rusev B, Fassan M, Antonello D, Sadakari Y, Castelli P, Zamboni G, Maitra A, Salvia R, Hruban RH, Bassi C, Capelli P, Lawlor RT, Goggins M, Scarpa A. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol 2014;233:217-227. PMC4057302

Kanda M, Matthaei H, Wu J, Hong SM, Yu J, Borges M, Hruban RH, Maitra A, Kinzler K, Vogelstein B, Goggins M. Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia. Gastroenterology 2012;142:730-733.e9. Epub 2012 Jan 5. PMC3321090

Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR*, Goggins M*, Klein AP*. Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene. Science 2009; 324:217.: PMC2684332 *senior authors.

Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z, Topazian M, Takahashi N, Fletcher J, Petersen G, Klein AP, Axilbund J, Griffin C, Syngal S, Saltzman JR, Mortele KJ, Lee J, Tamm E, Vikram R, Bhosale P, Margolis D, Farrell J, Goggins M. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 2012;142:796-804. PMC3321068

Kanda M, Knight S, Topazian M, Syngal S, Farrell JJ, Lee J, Kamel I, Lennon AM, Borges M, Young A, Fujiwara S, Seike J, Eshleman J, Hruban RH, Canto MI, Goggins M. Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut 2013;62:1024-33 PMC3893110

Hong SM, Vincent A, Kanda M, Leclerc J, Omura N, Borges M, Klein AP, Canto M, Hruban RH, Goggins M. Genome-wide somatic copy number alterations in low-Grade PanINs and IPMNs from individuals with a family history of Pancreatic Cancer. Clin Cancer Res 2012;18:4303-12.

Hong SM, Omura N, Vincent A, Li A, Knight S, Yu J, Hruban RH, Goggins M. Genome-wide CpG island profiling of intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res 2012;18:700-12. PMC3271174

Vincent A, Omura N, Hong SM, Jaffe A, Eshleman J, Goggins M. Genome-Wide Analysis of Promoter Methylation Associated with Gene Expression Profile in Pancreatic Adenocarcinoma. Clin Cancer Res 2011;17:4341-54 PMC3131423

Goggins M. Markers of Pancreatic Cancer: Working Toward Early Detection. Clin Cancer Res 2011;17:635-7. PMC3079322

Hong SM, Heaphy CM, Shi C, Eo SH, Cho H, Meeker AK, Eshleman JR, Hruban RH, Goggins M. Telomeres are shortened in acinar-to-ductal metaplasia lesions associated with pancreatic intraepithelial neoplasia but not in isolated acinar-to-ductal metaplasias. Mod Pathol 2011;24:256-66. PMC3166222

Hong SM, Li A, Olino K, Wolfgang CL, Herman JM, Schulick RD, Iacobuzio-Donahue C, Hruban RH, Goggins M. Loss of E-Cadherin Expression and Outcome among Patients with Resectable Pancreatic Adenocarcinomas. Mod Pathol 2011; 24(9):1237-47. PMC3155013

Li A, Omura N, Hong SM, Vincent A, Walter K, Griffith M, Borges M, Goggins M. Pancreatic cancers epigenetically silence SIP1, hypomethylate and overexpress miR-200a/-200b, in association with elevated circulating miR-200a and miR-200b levels. Cancer Research 2010; 70(13):5226-37 PMC3130565

Walter K, Omura N, Hong SM, Griffith M, Vincent A, Borges M, Goggins M. Overexpression of Smoothened activates the Sonic Hedgehog signaling pathway in pancreatic cancer associated fibroblasts. Clin Cancer Res. 2010; 16:1781-9. PMCID: PMC2846609

Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321(5897):1801-6. PMID: 18772397



 


Copyright © 2017 Johns Hopkins University. All Rights Reserved